Core Viewpoint - EDAP TMS S.A. has appointed David Horn to its Board of Directors, effective February 11, 2026, enhancing the board's expertise in strategic growth and transformation [1][2]. Group 1: Appointment Details - David Horn brings extensive experience in capital markets and the medical device industry, having served as President and CFO of Seer, Inc. since 2023 and previously at Morgan Stanley for over 20 years [3]. - Horn will be a member of the Audit Committee and Nominations Committee, contributing to strategic planning and execution [2][3]. Group 2: Company Leadership and Strategy - The Chairman of the Board, Lance Willsey, expressed confidence in Horn's ability to support EDAP's growth strategy and enhance shareholder value [3]. - Horn emphasized the importance of EDAP's innovation in focal therapy technology and its potential to expand clinical indications [4]. Group 3: Board Changes - Glen French has stepped down from the Board of Directors effective February 10, 2026, with appreciation expressed for his contributions [4][5].

Core Insights - EDAP TMS SA will present at the Piper Sandler 37th Annual Healthcare Conference on December 2, 2025, with CEO Ryan Rhodes and CFO Ken Mobeck hosting 1x1 investor meetings [1][2] Company Overview - EDAP TMS SA is a leader in robotic energy-based therapies, developing and distributing minimally invasive medical devices using ultrasound technology [3] - The company introduced the Focal One® system, a leading prostate focal therapy, which is controlled by urologists and has potential applications beyond prostate cancer [3]

Core Points - EDAP TMS SA, a leader in robotic energy-based therapies, will present at the Jefferies Global Healthcare Conference in London on November 18, 2025 [1] - The presentation will be led by CEO Ryan Rhodes and will include 1x1 investor meetings [1] - The conference will take place from November 18-20, 2025, at the Waldorf – Aldwych [2] Company Overview - EDAP TMS SA specializes in developing, manufacturing, promoting, and distributing minimally invasive medical devices using ultrasound technology [3] - The company is known for its Focal One® system, which is a leading prostate focal therapy controlled by urologists, with potential applications beyond prostate cancer [3] - EDAP TMS aims to combine advanced imaging, robotics, and precise non-invasive energy delivery in its medical devices [3]

Core Insights - EDAP TMS SA will participate in the UBS Global Healthcare Conference, hosting 1x1 investor meetings on November 10, 2025 [1][2] Company Overview - EDAP TMS SA is a leader in robotic energy-based therapies, developing and distributing minimally invasive medical devices using ultrasound technology [3] - The company introduced the Focal One® system, a leading prostate focal therapy, which is controlled by urologists and has potential applications beyond prostate cancer [3]

Core Points - EDAP TMS SA will transition to U.S. reporting status effective January 1, 2026, ceasing to qualify as a foreign private issuer under SEC rules [1] - This change reflects the company's commitment to transparency and regulatory best practices, aiming to strengthen relationships with shareholders and attract institutional investors [2] Company Overview - EDAP TMS SA is a leader in robotic energy-based therapies, developing and distributing minimally invasive medical devices using ultrasound technology [2] - The company has introduced the Focal One® system, a leading prostate focal therapy, with potential applications beyond prostate cancer [2]

Company Overview - EDAP TMS SA is a global leader in robotic energy-based therapies, focusing on minimally invasive medical devices utilizing ultrasound technology [3] - The company has developed the Focal One®, a leading prostate focal therapy device, which is controlled by urologists and has potential applications beyond prostate cancer [3] Upcoming Event - Ryan Rhodes, the CEO of EDAP TMS, will present and host one-on-one investor meetings at the Jefferies Global Healthcare Conference from June 3-5, 2025, in New York City [1] - The presentation is scheduled for June 5th from 4:20 to 4:50 PM ET, and it will be available via a live and archived webcast [2]

Core Viewpoint - EDAP TMS SA will release its financial results for Q1 2025 on May 15, 2025, before market opening [1] Group 1: Conference Call Details - A conference call and webcast will be held on May 15, 2025, at 8:30 am EDT [2] - The call will feature CEO Ryan Rhodes, CFO Ken Mobeck, and Chief Accounting Officer François Dietsch [2] - Dial-in numbers include 1-800-267-6316 for domestic and 1-203-518-9783 for international calls, with the passcode "EDAP" [3] Group 2: Company Overview - EDAP TMS SA is a leader in robotic energy-based therapies, focusing on minimally invasive medical devices using ultrasound technology [3] - The company has introduced the Focal One® system for prostate focal therapy, which is controlled by urologists and has potential applications beyond prostate cancer [3]